Are there conditions where you would specifically favor using the subcutaneous over the IV formulation of pertuzumab/trastuzumab?

With really long treatment programs like TCHP, utilizing SQ HP can really help cut down on infusion time, which is helpful as it allows a little more flexibility in booking the patients in the infusion center with regards to start times.

Specific conditions I favor nclude, but not limited to the following:

1. Patient is receiving a non-IV containing regimen

2. Patient has limited peripheral access or no central access

3. Patient has a current central access that poses an infection risk or otherwise has an indication to be removed...

Perhaps in a patient who is having problems with local reactions (not very common)